New shot could shrink nasal polyps without surgery
NCT ID NCT05281523
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tested a biologic drug called depemokimab in 264 adults with chronic sinusitis and nasal polyps. Participants received either the drug or a placebo as a shot under the skin. The study measured changes in polyp size and nasal blockage over 52 weeks. The goal is to see if depemokimab can reduce symptoms and the need for surgery or steroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Depemokimab (a biologic drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new treatment option to shrink nasal polyps and ease breathing without needing surgery or steroids.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not work better than placebo, and side effects like allergic reactions or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASAL POLYPS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Tucson, Arizona, 85724, United States
-
GSK Investigational Site
Roseville, California, 95661, United States
-
GSK Investigational Site
New Haven, Connecticut, 06520, United States
-
GSK Investigational Site
Hialeah, Florida, 33012, United States
-
GSK Investigational Site
Baltimore, Maryland, 21287, United States
-
GSK Investigational Site
Grand Rapids, Michigan, 55446, United States
-
GSK Investigational Site
Columbia, Missouri, 65212, United States
-
GSK Investigational Site
Oklahoma City, Oklahoma, 73120, United States
-
GSK Investigational Site
Fort Worth, Texas, 76109, United States
-
GSK Investigational Site
McAllen, Texas, 78503, United States
-
GSK Investigational Site
McKinney, Texas, 75070, United States
-
GSK Investigational Site
San Antonio, Texas, 78258, United States
-
GSK Investigational Site
Norfolk, Virginia, 23507, United States
-
GSK Investigational Site
Morgantown, West Virginia, 26506-9200, United States
-
GSK Investigational Site
Changsha, 410013, China
-
GSK Investigational Site
Chengdu, 610041, China
-
GSK Investigational Site
Guangzhou, 510000, China
-
GSK Investigational Site
Hangzhou, 310000, China
-
GSK Investigational Site
Nanjing, 210009, China
-
GSK Investigational Site
Shanghai, 200003, China
-
GSK Investigational Site
Shanghai, 200031, China
-
GSK Investigational Site
Suzhou, China
-
GSK Investigational Site
Wuhan, 430060, China
-
GSK Investigational Site
Xiamen, 361004, China
-
GSK Investigational Site
Zhongshan, 528400, China
-
GSK Investigational Site
Zibo Shandong Province, 255036, China
-
GSK Investigational Site
Bologna, 40139, Italy
-
GSK Investigational Site
Catania, 95123, Italy
-
GSK Investigational Site
Milan, 20132, Italy
-
GSK Investigational Site
Naples, 80131, Italy
-
GSK Investigational Site
Padova, 35100, Italy
-
GSK Investigational Site
Pisa, Italy
-
GSK Investigational Site
Roma, 00128, Italy
-
GSK Investigational Site
Roma, 00168, Italy
-
GSK Investigational Site
Rozzano MI, 20089, Italy
-
GSK Investigational Site
Varese, 21100, Italy
-
GSK Investigational Site
Aichi, 471-8513, Japan
-
GSK Investigational Site
Chiba, 262-0015, Japan
-
GSK Investigational Site
Chiba, 272-0143, Japan
-
GSK Investigational Site
Gunma, 373-8585, Japan
-
GSK Investigational Site
Hyōgo, 650-0047, Japan
-
GSK Investigational Site
Hyōgo, 665-0827, Japan
-
GSK Investigational Site
Ibaraki, 309-1793, Japan
-
GSK Investigational Site
Kanagawa, 211-8533, Japan
-
GSK Investigational Site
Nagano, 395-8505, Japan
-
GSK Investigational Site
Shiga, 525-8585, Japan
-
GSK Investigational Site
Shizuoka, 420-0853, Japan
-
GSK Investigational Site
Tokyo, 142-8666, Japan
-
GSK Investigational Site
?Od?, 90-153, Poland
-
GSK Investigational Site
Gdansk, 80-214, Poland
-
GSK Investigational Site
Katowice, 40-611, Poland
-
GSK Investigational Site
Krakow, 30-033, Poland
-
GSK Investigational Site
Krakow, 31-513, Poland
-
GSK Investigational Site
Lubin, 59-300, Poland
-
GSK Investigational Site
Nadarzyn, 05-830, Poland
-
GSK Investigational Site
Poznan, 60-355, Poland
-
GSK Investigational Site
Strzelce Opolskie, 47-100, Poland
-
GSK Investigational Site
Brasov, 500091, Romania
-
GSK Investigational Site
Brasov, 500283, Romania
-
GSK Investigational Site
Bucharest, 014146, Romania
-
GSK Investigational Site
Bucharest, 014452, Romania
-
GSK Investigational Site
Cluj-Napoca, 400349, Romania
-
GSK Investigational Site
Timișoara, 300643, Romania
-
GSK Investigational Site
Barcelona, 08022, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Barcelona, 08041, Spain
-
GSK Investigational Site
Barcelona, 08907, Spain
-
GSK Investigational Site
Jerez de la Frontera, 11407, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Pamplona, 31008, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Seville, 41009, Spain
-
GSK Investigational Site
Valladolid, 47005, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Gothenburg, SE-413 45, Sweden
-
GSK Investigational Site
Lund, SE-221 85, Sweden
-
GSK Investigational Site
Stockholm, SE-114 86, Sweden
-
GSK Investigational Site
Stockholm, SE-171 76, Sweden
-
GSK Investigational Site
Ankara, 06230, Turkey (Türkiye)
-
GSK Investigational Site
CapaIstanbul, 34093, Turkey (Türkiye)
-
GSK Investigational Site
Izmir, 35330, Turkey (Türkiye)
-
GSK Investigational Site
Tekirdağ, 59100, Turkey (Türkiye)